Rockwell Medical Inc

NASDAQ RMTI

Data sourced from

and

Daily

Download Data

Rockwell Medical Inc Price to Book Ratio (P/B) on June 03, 2024: 2.57

Rockwell Medical Inc Price to Book Ratio (P/B) is 2.57 on June 03, 2024, a -61.50% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Rockwell Medical Inc 52-week high Price to Book Ratio (P/B) is 5,870.70 on August 11, 2023, which is 228,331.99% above the current Price to Book Ratio (P/B).
Rockwell Medical Inc 52-week low Price to Book Ratio (P/B) is 0.00 on March 18, 2024, which is -99.91% below the current Price to Book Ratio (P/B).
Rockwell Medical Inc average Price to Book Ratio (P/B) for the last 52 weeks is 26.89.

NASDAQ: RMTI

Rockwell Medical Inc

CEO	Dr. Mark Strobeck Ph.D.
IPO Date	Jan. 27, 1998
Location	United States
Headquarters	30142 South Wixom road, Wixom, MI, United States, 48393
Employees	237
Sector	Healthcare
Industry	Drug manufacturers - specialty & generic

Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Key trends